Table 2 Primary evaluation of the adverse events for all patients

From: Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial

Patient #

Early AEs

Comments

Late AEs

Comments

Patient 1

Headache, tailbone pain, blurry vision

Resolved with OTC

Heel pain, numbness of hands & feet, foot skin lesion, fatigue, spasticity, neuropathic pain in the chest

Resolved

Patient 2

Headache, cold flu-like congestion, fever, low back pain

Resolved with OTC

Skin breakdown of heal, depression

Resolved

Patient 3

Headache, tailbone pain, stomach pain

Resolved with OTC

Skin breakdown of heal, depression

Resolved

Patient 4

Headache, general hip pain

Resolved

N/A

Resolved

Patient 5

Sharp back pain, dizziness, hip pain

Resolved with OTC

Warming sensation felt in MRI, left buttock lesion, left hip pain

Resolved with Tramadol

Patient 6

Foot pain

Resolved

Hip fracture (fall from the chair)

Not related to study

Patient 7

Headache, bilateral hip and leg pain

Resolved

Sweating below the waist in both legs

Resolved

Patient 8

Low-grade fever, arm pain, headache

Resolved with OTC

Bilateral lower leg spasms

Resolved

Patient 9

Headache, tailbone soreness, tightness

Resolved

Skin breakdown on the ulnar aspect of the left fifth MCP

Resolved

Patient 10

Headache and dysreflexia

Resolved with OTC

Upper back pressure injury

Resolved